The Hamilton Enhanced Canadian Bank ETF (TSX: HCAL) has had a spectacular year. Its unit price ranged from a 52-week low of $27.36 to a high of $52.24 — and with distributions included, its trailing one-year total return lands north of 80% by any source you check. It didn't just ride the Canadian bank rally; its built-in 25% leverage amplified it, and HCAL decisively outperformed its unlevered benchmark.
So why does our scoring engine rate it a HOLD, at 70/100 — and not a BUY?
Because performance and health are not the same question. Here's the full picture, factor by factor, including the one number that almost no HCAL review mentions.
What HCAL actually is
HCAL is not a covered-call fund, and it doesn't use derivatives. Per Hamilton's own documentation, it holds Canada's Big Six banks (tracking the Solactive Equal Weight Canada Banks Index) with approximately 25% cash leverage — borrowed money, provided by a Canadian financial institution, layered on top of an ordinary equal-weight bank portfolio to target 1.25x the index's return.
That design has one honest, predictable consequence: it makes good years better and bad years worse. There's no options overlay softening the ride. When Canadian banks rally — as they have, dramatically — HCAL beats them. When banks fall, HCAL falls roughly 1.25x as hard. That 52-week low of $27.36 isn't ancient history; it was within the past twelve months.
HCAL pays monthly cash distributions and currently yields about 3.3% — modest by design, since this fund's pitch is amplified bank exposure, not income maximization.
The good: no erosion, and a benchmark genuinely beaten
Our engine's highest-weighted factor measures what we call NAV erosion: whether a fund's total return (price change plus every dollar it actually paid out) is keeping pace with a comparable benchmark — because a fund that persistently lags its own sector while paying distributions may be quietly handing investors their own capital back.
HCAL passes this test easily. Measured against ZEB, the unlevered equal-weight Canadian bank ETF, HCAL's total return has run meaningfully ahead — our engine measures the gap at roughly +6 percentage points per year over its evaluation window, and independent one-year comparisons show an even wider spread (HCAL up 80%+ against ZEB's mid-60s). The leverage is doing exactly what the prospectus says it does, in the direction every holder hoped.
On this factor, HCAL earns a perfect score. There is no return-of-capital story here. The distribution is small relative to what the fund earns, and the fund is genuinely creating value against its sector.
If our engine only measured performance, HCAL would be an easy BUY.
The problem: the most expensive yield in our entire database
Here's the number that changes the picture.
HCAL's true cost of ownership — including the financing cost of that 25% leverage, which the headline management fee excludes — comes out to roughly 2.1% per year based on independent reporting (sources range from about 1.6% to 2.2%; Hamilton's stated management fee alone is 0.65%, before leverage costs).
A 2.1% cost isn't automatically disqualifying. Some funds charge that much and earn it. The question our engine asks is different from the one most reviews ask: not "is the fee high?" but "what does the fee buy you?"
We measure every fund's cost as a percentage of the yield it delivers. Across the 40+ Canadian income funds and dividend stocks in our database, the median fund spends roughly 11% of its distribution yield on fees. A fund charging 0.75% to deliver a 10% yield is spending about 7% of what it pays you. Even the expensive leveraged covered-call funds — with fees north of 2.5% — typically deliver 9-13% yields, keeping their ratio in the 20-26% range.
HCAL charges approximately 2.1% to deliver a 3.3% yield.
That's a fee-to-yield ratio of roughly 65% — the most extreme in our entire coverage universe, about five times the median. Nearly two-thirds of what this fund yields is consumed by its own cost structure before a dollar reaches you.
Is that unfair to HCAL?
A reasonable objection: HCAL isn't sold as an income fund. Its yield is a byproduct; the product is leveraged capital appreciation. Judging it by fee-to-yield, the argument goes, measures it against a job it never applied for.
There's something to that — and it's exactly why HCAL still scores 70/100 rather than something punitive. Its performance factors are excellent. But we'd push back on letting it fully off the hook, for two reasons.
First, HCAL pays a monthly cash distribution and is widely held inside income-oriented Canadian portfolios, TFSAs, and retirement accounts alongside covered-call funds. It is marketed with a yield figure. Investors comparing it against other monthly payers deserve to know that its cost-per-dollar-of-income is in a different universe than anything else on that comparison table.
Second — and this is the part that matters beyond HCAL — a high total-cost structure is a permanent headwind, while a leverage-driven performance edge is conditional. The 2.1% is charged in good years and bad. The +6 points of benchmark outperformance exists only in years when banks go up. In a flat year for Canadian banks, HCAL's expected edge over ZEB approaches zero while its cost disadvantage stays fully intact. In a down year, both work against you at once.
The verdict
HCAL: 70/100 — HOLD.
What the score is saying, in plain English: this fund is healthy, it does exactly what it promises, and it has delivered spectacularly in current conditions — but its cost structure relative to what it pays out is the single most extreme in our database, and that's a permanent feature, not a temporary one.
For an investor who specifically wants leveraged Canadian bank exposure, understands the drawdown math, and doesn't care about the yield — HCAL is a coherent product having a great run. For an income investor comparing monthly payers on yield, HCAL's 3.3% is the most expensively produced yield we track, and cheaper routes to Canadian bank income exist (including simply holding ZEB, or the banks themselves).
Performance answers "how has it done." Health answers "what are you actually paying for, and what happens when conditions change." Those are different questions — and the second one is the one our scoring engine exists to ask.
Data as of late July 2026. Scores and figures update as market data changes — see the live HCAL analysis page for current numbers. This is analysis, not financial advice; see our methodology and disclaimer.